Investors largely expected the FOMC to cut rates by a quarter point.The Fedread more
India could benefit from the fallout in the U.S.-China trade war, experts told CNBC — but much-needed reforms on land and labor could prove to be a challenge for companies...Asia Economyread more
The FAA administrator's comments come on the eve of his visit to Boeing facilities outside Seattle. While there, he's scheduled to meet with Boeing executives and be briefed...Airlinesread more
The photo depicts Canadian leader Justin Trudeau wearing a turban and robe, with dark makeup on his hands, face and neck. Liberal Party spokesman confirms the photo is of...Electionsread more
As the Fed was meeting to consider cutting interest rates, it lost control of the very benchmark rate that it manages.Market Insiderread more
CBS, CNN and other major media companies are starting to pull e-cigarette advertising off their airways, as the death toll from a mysterious vaping-related illness continues...Health and Scienceread more
The U.S. Federal Reserve on Wednesday cut its overnight rate by 25 basis points to a range of 1.75% to 2%, a move that was widely expected. The central bank, however, appeared...Asia Marketsread more
Investors bought bank stocks because there's a chance the Federal Reserve's interest rate cut may "put an end to this artificially inverted yield curve," Jim Cramer says.Mad Money with Jim Cramerread more
AT&T is considering selling DirecTV, according to a report in the Wall Street Journal.Technologyread more
The Facebook CEO will talk to policymakers "about future internet regulation," according to a spokesperson.Technologyread more
Disney CEO Bob Iger writes in his autobiography that he believes he would have discussed combining Disney with Apple had Steve Jobs lived.Technologyread more
Shares of Avalanche Biotechnologies plummeted 56 percent Tuesday after the company reported disappointing results on its eye disease drug. Despite the steep selloff, the company's CEO wouldn't say whether he would buy more shares.
When asked directly Tuesday on CNBC's "Fast Money" if he was using the selloff as an opportunity to pick up more stock, CEO Thomas Chalberg passed on the question, pointing instead to the fact that he is "one of the largest shareholders" and that he remains committed to the long term.
Chalberg owns 1,099,000 shares, and the total market value of his holdings as of Tuesday's close was $43 million. In the last six months, he sold a total of 112,000 shares. Between Tuesday night's data announcement and Wednesday's trading session, his holdings lost approximately $24 million.
The stock was up less than 1 percent Wednesday.
It's been a wild ride for shareholders since the company went public last July. The stock nearly tripled after its IPO, but at Tuesday's closing, it was down 37 percent since going public.
The Avalanche saga is a stark reminder of the profit and potential pitfalls that come with investing in individual biotech names. Avalanche's main treatment is designed to combat a chronic eye disease that causes blindness. Beyond that drug, the company's pipeline remains small, which makes owning the stock a feast or famine proposition.
"Basically there are two categories of biotech. There's binary biotech, which this falls in, and there are biotechs that have a tremendous pipeline and drugs out on the market, which this does not fall in," said "Fast Money" trader Guy Adami. "This is a lottery ticket."